Recent studies have shown that IFN-γ upregulates immunosuppressive molecules such as PD-L1, PD-L2 and IDO1, in cancer and host cells (38, 39), thereby increasing the response likelihood to ICIs therapy. This evidence concerns the gene PDCD1LG2 and cancer.